RxDoctor Payments Data

Laura Surman

Nurse Practitioner · Barneveld, NYNPI 1508951179

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 64 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$220
  • Abbott$144
  • Pfizer$123
  • AbbVie$114
  • Novo Nordisk$109
  • Lilly USA, LLC$82
  • plus $328 from 11 others

What the payments were for

  • Food & beverage$1,10999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,120 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$43,694
Medicare patients
201
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$90,869
JardianceEmpagliflozin50$69,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$50,976
JanuviaSitagliptin Phosphate49$49,893
FarxigaDapagliflozin Propanediol35$45,484
OzempicSemaglutide36$43,584
XareltoRivaroxaban34$35,274
RybelsusSemaglutide27$29,198
TradjentaLinagliptin38$28,390
MounjaroTirzepatide12$18,108
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$16,461
TrulicityDulaglutide19$15,712
MyrbetriqMirabegron14$9,005
Breo ElliptaFluticasone/Vilanterol12$8,046
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$29$98,14688 claims
PfizerEliquis$123$90,86994 claims
Novo NordiskOzempic, Rybelsus$109$72,78363 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$220$63,86568 claims
MerckJanuvia$16$49,89349 claims
AstraZenecaFarxiga$68$45,48435 claims
Johnson & JohnsonXarelto$25$35,27434 claims
Lilly USA, LLCMounjaro, Trulicity$82$33,81931 claims
BayerKerendia$33$7,13111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Barneveld

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →